Monitor the proxy statement filing and stockholder vote timeline. The deal's closing is tied to the Treeline merger — any delay or termination of that merger would likely scuttle this transaction as well.
Price Chart
Executive Summary
Standard BioTools terminated its prior agreement to sell its Mass Cytometry business to Multiplex Bio and entered into a new Share and Asset Purchase Agreement with Element Biosystems (a GMT Venture subsidiary) for $5.5 million in cash, subject to customary adjustments. The deal is conditioned on stockholder approval and the closing of Standard BioTools' pending merger with Treeline Biosciences, and is expected to close by end of 2026. The company states the new transaction increases net cash position by approximately $15 million relative to the prior deal by eliminating a $10 million working capital loan obligation.
Key Financial Metrics
Key Facts
- Standard BioTools terminated the Multiplex Bio purchase agreement and entered into a new agreement with Element Biosystems for $5.5 million in cash.
- The new deal eliminates a $10 million working capital loan that was required under the Multiplex Bio agreement.
- GMT Venture paid $1.0 million of the $1.5 million Multiplex Bio termination fee on Standard BioTools' behalf.
- The transaction is conditioned on stockholder approval and the closing of the Treeline merger, with an outside date of June 30, 2027.
- Standard BioTools will pay a $1.0 million termination fee to Element under specified termination scenarios.
Financial Impact
The $5.5 million cash purchase price plus elimination of a $10 million working capital loan obligation improves Standard BioTools' net cash position by approximately $15 million versus the prior deal, per the company's statement.
Risk Factors
- Stockholder approval may not be obtained.
- The Treeline merger may not close, which is a condition to this transaction.
- A superior proposal for the Mass Cytometry business could emerge, triggering termination and a $1.0 million fee.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-038110 |
| Document: ef20082995_8k.htm | 0001140361-26-038110 |
| Document: ef20082995_ex99-1.htm | 0001140361-26-038110 |
| Document: 0001140361-26-038110-index-headers.html | 0001140361-26-038110 |
| Document: 0001140361-26-038110-index.html | 0001140361-26-038110 |
| Document: 0001140361-26-038110.txt | 0001140361-26-038110 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | EFFECT | $0.6400 $0.6056 | ▼ −5.38% | ▼ −4.85% | $0.5978 (−6.59%) |
Oct 21, 2026 5d ago | S-4/A | $0.6500 $0.6400 | ▲ +1.54% | ▲ +0.36% | $0.5978 (+8.03%) |
Oct 9, 2026 16d ago | S-4/A | $0.6578 $0.6589 | ▲ +0.17% | ▲ +0.18% | $0.5978 (−9.12%) |
Oct 5, 2026 20d ago | 425 | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.5978 (−17.20%) |
Oct 5, 2026 20d ago | 8-K | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.5978 (−17.20%) |
Oct 5, 2026 20d ago | Press Release | $0.7220 $0.6787 | ▼ −6.00% | ▼ −5.76% | $0.5978 (−17.20%) |
Sep 30, 2026 25d ago | 425 | $0.7283 $0.7447 | ▲ +2.25% | ▲ +1.51% | $0.5978 (−17.92%) |
Sep 30, 2026 25d ago | 8-K | $0.7283 $0.7447 | ▲ +2.25% | ▲ +1.51% | $0.5978 (−17.92%) |
Jul 29, 2026 12w ago | 425 | $0.8739 $0.8973 | ▲ +2.68% | ▲ +1.00% | $0.5978 (−31.59%) |
Jul 28, 2026 12w ago | Press Release | $0.7947 $0.8739 | ▲ +9.97% | ▲ +11.50% | $0.5978 (−24.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers